Brandon Couillard
Stock Analyst at Wells Fargo
(3.40)
# 537
Out of 5,182 analysts
169
Total ratings
44.57%
Success rate
5.63%
Average return
Main Sectors:
Stocks Rated by Brandon Couillard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHR Danaher | Maintains: Equal-Weight | $240 → $212 | $178.98 | +18.45% | 6 | Apr 22, 2026 | |
| BLLN BillionToOne | Maintains: Equal-Weight | $110 → $90 | $78.23 | +15.05% | 2 | Mar 5, 2026 | |
| NTRA Natera | Maintains: Equal-Weight | $205 → $215 | $200.17 | +7.41% | 4 | Feb 27, 2026 | |
| A Agilent Technologies | Maintains: Overweight | $175 → $165 | $114.87 | +43.64% | 26 | Feb 26, 2026 | |
| RGEN Repligen | Maintains: Overweight | $190 → $180 | $117.43 | +53.28% | 4 | Feb 25, 2026 | |
| CDNA CareDx | Maintains: Equal-Weight | $18 → $21 | $21.91 | -4.15% | 5 | Feb 25, 2026 | |
| MYGN Myriad Genetics | Maintains: Equal-Weight | $6.5 → $6 | $4.84 | +23.97% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Overweight | $120 → $125 | $83.09 | +50.44% | 3 | Feb 20, 2026 | |
| AVTR Avantor | Maintains: Overweight | $16 → $14 | $7.86 | +78.12% | 6 | Feb 13, 2026 | |
| WAT Waters | Maintains: Equal-Weight | $415 → $355 | $300.73 | +18.05% | 8 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $155 | $66.07 | +134.60% | 7 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $76 | $53.51 | +42.03% | 3 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $83 → $94 | $99.42 | -5.45% | 5 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $107 → $110 | $85.18 | +29.14% | 4 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $635 → $675 | $470.22 | +43.55% | 8 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $1,450 | $1,262.48 | +14.85% | 7 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $3.56 | +26.58% | 2 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $55 | $36.26 | +51.68% | 7 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $265 → $340 | $279.34 | +21.72% | 13 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $265 → $340 | $282.40 | +20.40% | 13 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $260 | $177.28 | +46.66% | 11 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $77 → $80 | $76.12 | +5.10% | 6 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $23 | $26.49 | -13.17% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $2.59 | +401.93% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.01 | - | 11 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $11 | $2.82 | +290.07% | 2 | Oct 13, 2017 |
Danaher
Apr 22, 2026
Maintains: Equal-Weight
Price Target: $240 → $212
Current: $178.98
Upside: +18.45%
BillionToOne
Mar 5, 2026
Maintains: Equal-Weight
Price Target: $110 → $90
Current: $78.23
Upside: +15.05%
Natera
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $205 → $215
Current: $200.17
Upside: +7.41%
Agilent Technologies
Feb 26, 2026
Maintains: Overweight
Price Target: $175 → $165
Current: $114.87
Upside: +43.64%
Repligen
Feb 25, 2026
Maintains: Overweight
Price Target: $190 → $180
Current: $117.43
Upside: +53.28%
CareDx
Feb 25, 2026
Maintains: Equal-Weight
Price Target: $18 → $21
Current: $21.91
Upside: -4.15%
Myriad Genetics
Feb 24, 2026
Maintains: Equal-Weight
Price Target: $6.5 → $6
Current: $4.84
Upside: +23.97%
Guardant Health
Feb 20, 2026
Maintains: Overweight
Price Target: $120 → $125
Current: $83.09
Upside: +50.44%
Avantor
Feb 13, 2026
Maintains: Overweight
Price Target: $16 → $14
Current: $7.86
Upside: +78.12%
Waters
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $415 → $355
Current: $300.73
Upside: +18.05%
Feb 9, 2026
Upgrades: Overweight
Price Target: $155
Current: $66.07
Upside: +134.60%
Feb 6, 2026
Maintains: Overweight
Price Target: $70 → $76
Current: $53.51
Upside: +42.03%
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $83 → $94
Current: $99.42
Upside: -5.45%
Feb 3, 2026
Maintains: Equal-Weight
Price Target: $107 → $110
Current: $85.18
Upside: +29.14%
Dec 15, 2025
Maintains: Overweight
Price Target: $635 → $675
Current: $470.22
Upside: +43.55%
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $1,400 → $1,450
Current: $1,262.48
Upside: +14.85%
Dec 15, 2025
Maintains: Overweight
Price Target: $4 → $4.5
Current: $3.56
Upside: +26.58%
Dec 15, 2025
Maintains: Overweight
Price Target: $48 → $55
Current: $36.26
Upside: +51.68%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $265 → $340
Current: $279.34
Upside: +21.72%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $265 → $340
Current: $282.40
Upside: +20.40%
Jan 23, 2025
Maintains: Buy
Price Target: $285 → $260
Current: $177.28
Upside: +46.66%
Jan 23, 2025
Maintains: Hold
Price Target: $77 → $80
Current: $76.12
Upside: +5.10%
Feb 9, 2024
Downgrades: Hold
Price Target: $30 → $23
Current: $26.49
Upside: -13.17%
Jul 13, 2021
Initiates: Buy
Price Target: $13
Current: $2.59
Upside: +401.93%
Nov 2, 2017
Downgrades: Hold
Price Target: n/a
Current: $3.01
Upside: -
Oct 13, 2017
Maintains: Buy
Price Target: $9 → $11
Current: $2.82
Upside: +290.07%